Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
RWB Received an $8 Million Warrant Exercise From an Institutional Investor and Signed an Irrevocable $7 Million Non-Convertible Debenture Unit Financing Commitment
Red White & Bloom (OTCQX:RWBYF) announced that it has arranged the required cash for the closing of its previously announced acquisition of an Illinois Adult Use and Medical Cannabis Cultivation Center License and Associated Assets. Upon closing, and subject to regulatory approval, the Company intends to introduce both its Platinum Vape and High Times branded products into the Illinois market. “Surpassing USD $1 billion of adult-use sales in only its first year, Illinois has quickly developed into one of the most robust revenue markets in the United States. With the financing now secured, we are thrilled to be one step closer to bringing Red White & Bloom’s nationally-recognized brands to this market. The renewed optimism around the State permitting an additional 75 retail locations further highlights the enorm
(NEO: MMED)MindMed (OTCQB: MMEDF) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together..
Share this article
Share this article
ZUG, Switzerland, Feb. 11, 2021 /PRNewswire/ MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.
As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have already been synthesized by MindShift Compounds AG and related patent applications were filed by MindMed. MindMed plans to begin first-in-human Phase 1 clinical trials as early as Q1 2022 through its existing clinical trial platform for psychedelic and empathogenic compounds in Switzerland.